Optimizing vaccine design (antigen and adjuvant selection), concentrating on the role of CD4+ T cells in tumour vaccines, and combination immunotherapy will become new keys to increasing the efficacy of GBM vaccines. This evidence concerns the gene CD4 and glioblastoma.